Skip to main content
. 2017 Oct 19;8:179–190. doi: 10.2147/LCTT.S139647

Figure 2.

Figure 2

(A) Overall survival (initiation of first-line therapy until death) and (B) time to treatment discontinuation (initiation of first-line therapy until treatment discontinuation) among patients who received nab-paclitaxel plus carboplatin or gemcitabine plus carboplatin.

Abbreviations: nab-P/C, nab-paclitaxel plus carboplatin; Gem/C, gemcitabine plus carboplatin.